Investing
Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)
Published:
Last Updated:
We are seeing massive gap-ups this morning in stem cell stocks. President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding. What is interesting here is that this is not really new news other than the timing and the formality. The following prices are as of 8:19 AM EST.
- Aastrom Biosciences Inc. (NASDAQ: ASTM) +87% at $0.62
- Cytori Therapeutics Inc. (NASDAQ: CYTX) +38% at $3.20
- Geron Corp. (NASDAQ: GERN) +29% at $4.99
- Neostem Inc. (AMEX: NBS) NOT TRADED
- Osiris Therapeutics Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
- StemCells Inc. (NASDAQ: STEM) +55% at $2.15
- Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57
Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.
JON C. OGG
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
